EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
Active, not recruiting · NCT05284747 · Registry updated 2025-10-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction | Infarction, Necrosis, Non-ST Elevated Myocardial Infarction, Pathologic Processes, Pathological Conditions, Signs and Symptoms, ST-elevation myocardial infarction, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, nervous system disorder, stroke disorder, vascular disorder | Active, not recruiting | Phase 4 | 2025-10-06 | NCT05284747 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Amgen | 180 |
| Colorado Prevention Center | 6 |
119 results · Page 1 of 5
Research sites
Swipe the table sideways for more columns.